BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 20957396)

  • 21. Fructose-mediated non-enzymatic glycation: sweet coupling or bad modification.
    Schalkwijk CG; Stehouwer CD; van Hinsbergh VW
    Diabetes Metab Res Rev; 2004; 20(5):369-82. PubMed ID: 15343583
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protective role of antioxidative food factors in oxidative stress caused by hyperglycemia.
    Osawa T; Kato Y
    Ann N Y Acad Sci; 2005 Jun; 1043():440-51. PubMed ID: 16037265
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Amadori product on protein: structure and reactions.
    Baynes JW; Watkins NG; Fisher CI; Hull CJ; Patrick JS; Ahmed MU; Dunn JA; Thorpe SR
    Prog Clin Biol Res; 1989; 304():43-67. PubMed ID: 2675036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advanced glycation end-products and the progress of diabetic vascular complications.
    Jakus V; Rietbrock N
    Physiol Res; 2004; 53(2):131-42. PubMed ID: 15046548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protein glycation: creation of catalytic sites for free radical generation.
    Yim MB; Yim HS; Lee C; Kang SO; Chock PB
    Ann N Y Acad Sci; 2001 Apr; 928():48-53. PubMed ID: 11795527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications.
    Yamagishi S
    Ther Apher Dial; 2009 Dec; 13(6):534-9. PubMed ID: 19954478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protein crosslinking by the Maillard reaction: dicarbonyl-derived imidazolium crosslinks in aging and diabetes.
    Chellan P; Nagaraj RH
    Arch Biochem Biophys; 1999 Aug; 368(1):98-104. PubMed ID: 10415116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes.
    Cameron NE; Gibson TM; Nangle MR; Cotter MA
    Ann N Y Acad Sci; 2005 Jun; 1043():784-92. PubMed ID: 16037306
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ion-trap tandem mass spectrometric analysis of Amadori-glycated phosphatidylethanolamine in human plasma with or without diabetes.
    Nakagawa K; Oak JH; Higuchi O; Tsuzuki T; Oikawa S; Otani H; Mune M; Cai H; Miyazawa T
    J Lipid Res; 2005 Nov; 46(11):2514-24. PubMed ID: 16150834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Advanced glycosylation end products and chronic complications of diabetes mellitus].
    Méndez JD
    Gac Med Mex; 2003; 139(1):49-55. PubMed ID: 12666409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Substituted benzenediol Schiff bases as promising new anti-glycation agents.
    Choudhary MI; Abbas G; Ali S; Shuja S; Khalid N; Khan KM; Atta-ur-Rahman ; Basha FZ
    J Enzyme Inhib Med Chem; 2011 Feb; 26(1):98-103. PubMed ID: 20583858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Possible participation of advanced glycation end products in the pathogenesis of colorectal cancer in diabetic patients.
    Yamagishi S; Nakamura K; Inoue H; Kikuchi S; Takeuchi M
    Med Hypotheses; 2005; 64(6):1208-10. PubMed ID: 15823719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advanced glycation endproducts: what is their relevance to diabetic complications?
    Ahmed N; Thornalley PJ
    Diabetes Obes Metab; 2007 May; 9(3):233-45. PubMed ID: 17391149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification and quantification of phosphatidylethanolamine-derived glucosylamines and aminoketoses from human erythrocytes--influence of glycation products on lipid peroxidation.
    Breitling-Utzmann CM; Unger A; Friedl DA; Lederer MO
    Arch Biochem Biophys; 2001 Jul; 391(2):245-54. PubMed ID: 11437356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemical modification of proteins by methylglyoxal.
    Degenhardt TP; Thorpe SR; Baynes JW
    Cell Mol Biol (Noisy-le-grand); 1998 Nov; 44(7):1139-45. PubMed ID: 9846896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amadori-glycated phosphatidylethanolamine, a potential marker for hyperglycemia, in streptozotocin-induced diabetic rats.
    Sookwong P; Nakagawa K; Fujita I; Shoji N; Miyazawa T
    Lipids; 2011 Oct; 46(10):943-52. PubMed ID: 21732214
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of deoxy-D-fructosyl phosphatidylethanolamine as a non-enzymic glycation product of phosphatidylethanolamine and its occurrence in human blood plasma and red blood cells.
    Lertsiri S; Shiraishi M; Miyazawa T
    Biosci Biotechnol Biochem; 1998 May; 62(5):893-901. PubMed ID: 9648220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The glucose, glycotoxins and glycation products: the involvement into pathogenesis of microangiopathies, arteriolosclerosis and atherosclerosis].
    Titov VN; Shiriaeva IuK
    Klin Lab Diagn; 2011 Nov; (11):3-13. PubMed ID: 22312908
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advanced glycation end products and diabetic cardiovascular disease.
    Prasad A; Bekker P; Tsimikas S
    Cardiol Rev; 2012; 20(4):177-83. PubMed ID: 22314141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tandem mass spectrometry analysis of Amadori-glycated phosphatidylethanolamine in human plasma.
    Miyazawa T; Oak JH; Nakagawa K
    Ann N Y Acad Sci; 2005 Jun; 1043():280-3. PubMed ID: 16037249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.